Literature DB >> 18838208

Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.

Abraham Morgentaler1, Abdulmaged M Traish.   

Abstract

CONTEXT: The traditional belief that prostate cancer (PCa) growth is dependent on serum testosterone (T) level has been challenged by recent negative studies in noncastrated men.
OBJECTIVE: To provide an improved framework for understanding the relationship of PCa to serum T level that is consistent with current evidence and is based on established biochemical principles of androgen action within the prostate. EVIDENCE ACQUISITION: A literature search was performed of publications dating from 1941 to 2008 that addressed experimental and clinical effects of androgens on prostate growth. Review of studies investigating the prostatic effects of manipulation of androgen concentrations in human and animal studies, and in PCa cell lines. EVIDENCE SYNTHESIS: Prostate growth is exquisitely sensitive to variations in androgen concentrations at very low concentrations, but becomes insensitive to changes in androgen concentrations at higher levels. This pattern is consistent with the observation that androgens exert their prostatic effects primarily via binding to the androgen receptor (AR), and that maximal androgen-AR binding is achieved at serum T concentrations well below the physiologic range. A Saturation Model is proposed that accounts for the seemingly contradictory results in human PCa studies. Changes in serum T concentrations below the point of maximal androgen-AR binding will elicit substantial changes in PCa growth, as seen with castration, or with T administration to previously castrated men. In contrast, once maximal androgen-AR binding is reached the presence of additional androgen produces little further effect.
CONCLUSIONS: The evidence clearly indicates that there is a limit to the ability of androgens to stimulate PCa growth. A Saturation Model based on androgen-AR binding provides a satisfactory conceptual framework to account for the dramatic effects seen with castration as well as the minor impact of T administration in noncastrated men.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18838208     DOI: 10.1016/j.eururo.2008.09.024

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  130 in total

Review 1.  Adverse effects of testosterone replacement therapy: an update on the evidence and controversy.

Authors:  Anthony Grech; John Breck; Joel Heidelbaugh
Journal:  Ther Adv Drug Saf       Date:  2014-10

2.  Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy.

Authors:  Andrea Salonia; Andrea Gallina; Firas Abdollah; Alberto Briganti; Umberto Capitanio; Nazareno Suardi; Matteo Ferrari; Marco Raber; Renzo Colombo; Massimo Freschi; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2011-09-21       Impact factor: 4.226

Review 3.  [Intermittent androgen deprivation as therapy for androgen-sensitive prostate cancer. Sense or nonsense?].

Authors:  P Thelen; R-H Ringert; H Loertzer; A Strauß
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

4.  Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy.

Authors:  Eduard García-Cruz; Jorge Huguet; Marta Piqueras; Meritxell Pérez Márquez; Lluís Peri; Laura Izquierdo; Agustín Franco; Ricardo Alvarez-Vijande; María José Ribal; Antonio Alcaraz
Journal:  World J Urol       Date:  2011-08-11       Impact factor: 4.226

Review 5.  Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Authors:  Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

Review 6.  Prostate cancer: Testosterone therapy for hypogonadal men with prostate cancer.

Authors:  Salvatore P Catarinicchia; E David Crawford
Journal:  Nat Rev Urol       Date:  2016-07-19       Impact factor: 14.432

7.  The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy.

Authors:  Luis A Kluth; Shahrokh F Shariat; Christian Kratzik; Scott Tagawa; Guru Sonpavde; Malte Rieken; Douglas S Scherr; Karl Pummer
Journal:  World J Urol       Date:  2013-09-03       Impact factor: 4.226

Review 8.  The evaluation and management of testosterone deficiency: the new frontier in urology and men's health.

Authors:  William P Conners; Abraham Morgentaler
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

9.  Low serum testosterone levels are predictive of prostate cancer.

Authors:  Luigi Mearini; Alessandro Zucchi; Elisabetta Nunzi; Tommaso Villirillo; Vittorio Bini; Massimo Porena
Journal:  World J Urol       Date:  2011-11-09       Impact factor: 4.226

10.  Low free and bioavailable testosterone levels may predict pathologically-proven high-risk prostate cancer: a prospective, clinical trial.

Authors:  Göksel Bayar; Hakan Şirin; Mustafa Aydın; Ayşim Özağarı; Orhan Tanrıverdi; Mustafa Kadıhasanoğlu; Muammer Kendirci
Journal:  Turk J Urol       Date:  2017-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.